OlympiA is a randomized, double-blind, parallel group, placebo-controlled multicenter Phase III study organized to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1\/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.<\/p>\n\n\n\n
This international study is sponsored by AstraZeneca and the NCI and is conducted through a collaboration of industry leaders, including the Jules Bordet BrEAST clinical trials unit, Breast International Group (BIG), Frontier Science, the NRG clinical trials group, and Myriad Genetic Laboratories. <\/p>\n\n\n\n
Frontier Science provides project management, statistical leadership, design and analysis, randomization, data management, and programming. A separate firewalled Frontier Science statistical unit provides independent statistical analysis for OlympiA’s Data Monitoring Committee.<\/p>\n","protected":false},"excerpt":{"rendered":"
OlympiA investigates the efficacy and safety of olaparib as an adjuvant treatment in patients with germline BRCA1\/2 mutations and who are at high risk for HER2 negative primary breast cancer<\/p>\n","protected":false},"featured_media":475,"menu_order":8,"template":"","class_list":["post-474","project","type-project","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/www.frontierscience.org\/public\/wp-json\/wp\/v2\/project\/474"}],"collection":[{"href":"https:\/\/www.frontierscience.org\/public\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/www.frontierscience.org\/public\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.frontierscience.org\/public\/wp-json\/wp\/v2\/media\/475"}],"wp:attachment":[{"href":"https:\/\/www.frontierscience.org\/public\/wp-json\/wp\/v2\/media?parent=474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}